Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials

Collapse authors list.
Nguyen, Van Thu ORCID: 0000-0003-2197-0455, Rivière, Philippe, Ripoll, Pierre, Barnier, Julien, Vuillemot, Romain, Ferrand, Gabriel, Cohen-Boulakia, Sarah, Ravaud, Philippe, Boutron, Isabelle, Alawadhi, Solaf et al (show 59 more authors) , Amer-Yahia, Sihem, Ávila, Camila, Bafeta, Aïda, Baudry, Julia, Bollig, Claudia, Bonnet, Hillary, Boutron, Isabelle, Bouet, Marinette, Cabanac, Guillaume, Chaimani, Anna, Chavalarias, David, Chen, Yaolong, Chevance, Astrid, Cohen-Boulakia, Sarah, Coquery, Emmanuel, Conil, Francoise, Davidson, Mauricia, De Nale, Laura, Devane, Declan, Diard, Elise, Doreau, Bastien, Evrenoglou, Theodoros, Fabri, Alice, Feron, Gilles, Ferrand, Gabriel, Fezeu, Leopold, Fouet, Mathilde, El Chall, Lina Ghosn, Graña, Carolina, Grasselli, Giacomo, Grolleau, François, Hacid, Mohand-Said, Haddy, Loubna, Hansen, Camilla, Hohlfeld, Ameer, Hróbjartsson, Asbjørn, Julia, Chantal, Mavridis, Dimitris, Meerpohl, Joerg J, Meyer, Brice, Naidoo, Nivantha, Thu, Van Nguyen, Oikonomidi, Theodora, Pienaar, Elizabeth, Quirke, Fiona, Rada, Gabriel, Ravaud, Philippe, Ripoll, Pierre, Riveros, Carolina, Rivière, Philippe, Sauvant, Marie, Schmucker, Christine, Toumani, Farouk, Tovey, David, Vuillemot, Romain, Xia, Jun, Yu, Xuan, Zoletic, Emina and Zweigenbaum, Pierre (2021) Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials. Journal of Clinical Epidemiology, 130. pp. 107-116.

Access the full-text of this item by clicking on the Open Access link.

Abstract

<h4>Objectives</h4>Researchers worldwide are actively engaging in research activities to search for preventive and therapeutic interventions against coronavirus disease 2019 (COVID-19). Our aim was to describe the planning of randomized controlled trials (RCTs) in terms of timing related to the course of the COVID-19 epidemic and research question evaluated.<h4>Study design and setting</h4>We performed a living mapping of RCTs registered in the WHO International Clinical Trials Registry Platform. We systematically search the platform every week for all RCTs evaluating preventive interventions and treatments for COVID-19 and created a publicly available interactive mapping tool at https://covid-nma.com to visualize all trials registered.<h4>Results</h4>By August 12, 2020, 1,568 trials for COVID-19 were registered worldwide. Overall, the median ([Q1-Q3]; range) delay between the first case recorded in each country and the first RCT registered was 47 days ([33-67]; 15-163). For the 9 countries with the highest number of trials registered, most trials were registered after the peak of the epidemic (from 100% trials in Italy to 38% in the United States). Most trials evaluated treatments (1,333 trials; 85%); only 223 (14%) evaluated preventive strategies and 12 postacute period intervention. A total of 254 trials were planned to assess different regimens of hydroxychloroquine with an expected sample size of 110,883 patients.<h4>Conclusion</h4>This living mapping analysis showed that COVID-19 trials have relatively small sample size with certain redundancy in research questions. Most trials were registered when the first peak of the pandemic has passed.

Item Type:	Article
Uncontrolled Keywords:	COVID-NMA Consortium Team, Humans, Hydroxychloroquine, Epidemiologic Research Design, Sample Size, Internet, United States, Italy, Female, Male, Randomized Controlled Trials as Topic, Pandemics, Geographic Mapping, COVID-19, COVID-19 Drug Treatment
Depositing User:	Symplectic Admin
Date Deposited:	17 Feb 2021 09:30
Last Modified:	16 Mar 2024 06:52
DOI:	10.1016/j.jclinepi.2020.10.010
Open Access URL:	https://www.jclinepi.com/article/S0895-4356(20)311...
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3115733